Biosensors International Group Ltd. has entered into a licensing agreement with Eurocor GmbH, a group company of Opto Circuits (India) Ltd. for their drug eluting balloon (DEB) technology and related intellectual property (IP) rights in relation to the treatment of both coronary and peripheral artery disease. As a first step in this process, an original equipment manufacturer (OEM) arrangement is being implemented, whereby Biosensors will market and sell, under its own brand, DEBs manufactured by Eurocor.
June 19, 2013 — Coronary artery disease (CAD) is one of the world’s most prevalent and silent killers. Positron emission tomography (PET), which images miniscule abnormalities in cellular metabolism, can tip off clinicians about cardiac disasters waiting to happen — including sudden death from a heart attack — better than standard angiography, researchers revealed at the Society of Nuclear Medicine and Molecular Imaging’s 2013 Annual Meeting.
Magnetic resonance imaging (MRI) scans of children who have had chemotherapy can detect early changes in their hearts finds research in biomed Central's open access journal Journal of Cardiovascular Magnetic Resonance.
SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...
Valtech Cardio Ltd. announced that two patients diagnosed with severe mitral regurgitation (MR) have been treated successfully with its Transfemoral Cardioband Annuloplasty System.
Criteria for evaluating operator competency for performing coronary interventions should be expanded beyond procedure volume and include an evaluation of risk-adjusted outcomes, periodic case reviews of patient selection and other factors, according to a new report from the American College of Cardiology, the American Heart Association and the Society for Cardiovascular Angiography and Interventions.

Preliminary results from the ADVISE (Adenosine Vasodilator Independent Stenosis Evaluation) II trial confirm prior retrospective publications and demonstrate the clinical usefulness of an iFR/fractional flow reserve (FFR) hybrid approach to simplify lesion assessment and to save the use of hyperemic drugs in a significant number of patients. It was also announced that this hybrid iFR/FFR strategy, along with intravascular ultrasound (IVUS) guidance, will be used in the multi-center SYNTAX2 trial in Europe starting later this year.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Agfa began its global release of ICISTM View 3.0, the medical images and results viewer for the comprehensive ICIS enterprise imaging solution. The ICIS patient imaging data platform is a fundamental part of the company’s global e-health strategy. Building on its leadership in enterprise imaging management and web-enabled technology, Agfa HealthCare’s ICIS View 3.0 allows clinicians, specialists, and all other stakeholders to access all patient imaging data from any PACS or VNA, using a single viewer, to support continuity and productivity of patient care. This cost- effective solution leverages the hospital’s existing investment in technology, and provides access to the most current and relevant patient imaging data directly from the source.
St. Jude Medical Inc. announced U.S. Food and Drug Administration (FDA) approval to begin the EnligHTN IV Renal Denervation Study, the first U.S. trial using the EnligHTN Multi-Electrode Renal Denervation System to treat patients with drug-resistant high blood pressure.

Abbott has announced publication of positive outcomes from two European post-approval studies of the catheter-based MitraClip therapy for the treatment of mitral regurgitation (MR). Results from ACCESS-EU, a European prospective study that enrolled 567 patients at 14 sites, have been published in the Journal of the American College of Cardiology. In addition, findings of the investigator-sponsored German TRAnscatheter Mitral Valve Interventions (TRAMI) registry, which enrolled 1,064 patients at 20 German sites, were recently published in EuroIntervention.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Tryton Medical Inc. announced that the Nordic-Baltic Bifurcation Study Group will investigate the Tryton Side Branch Stent. The trial is a prospective, controlled, randomized, multicenter clinical study examining the role of final kissing balloon inflations in patient outcomes. A total of 150 patients will receive the Tryton Side Branch Stent with a drug-eluting stent, with evaluation by intravascular optical coherence tomography (OCT) imaging technology.
Mirada Medical collaborators has presented new positron emission tomography/magnetic resonance imaging (PET/MRI) research. The software supports both the hardware hybrid scanners and provides validated deformable registration for software based PET/CT (computed tomorgraphy)/MRI.
MIM Software Inc. has introduced a new version of MIM Encore that provides a single platform for viewing positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI) and nuclear medicine exams. Users will benefit from having all of the imaging data they need available on one workstation. Additionally, integrated quantitative analysis solutions are available for both cardiac and neuro PET and single photon emission computed tomography (SPECT) providing an all-in-one solution for Nuclear Medicine departments.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Siemens Healthcare has introduced the world’s first xSPECT system — combines the high sensitivity of single-photon emission computed tomography (SPECT) with the high specificity of computed tomography (CT), completely integrating the data from the two modalities, to generate high resolution and quantitative images. Meanwhile, Biograph mCT Flow is a new positron emission tomography/computed tomography (PET/CT) system that overcomes the limitations of conventional bed-based PET/CT with FlowMotion. This new technology moves the patient smoothly through the system’s gantry, while continuously acquiring PET data.
UltraSPECT announced the installation of its proprietary Wide Beam Reconstruction (WBR) software at nearly 10 healthcare facilities. The installations came as a result of the recent agreement between UltraSPECT and radiopharmaceutical provider PharmaLogic, under which PharmaLogic offers the WBR software as part of its patient-centered approach.
Siemens Healthcare has introduced Biograph mCT Flow, a positron emission tomography/computed tomography (PET/CT) system that, for the first time ever, overcomes the limitations of conventional bed-based PET/CT with FlowMotion, a revolutionary new technology that moves the patient smoothly through the system’s gantry, while continuously acquiring PET data. Biograph mCT Flow with FlowMotion takes routine image quality to a new level by enabling imaging protocols based on the organ’s need.